Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.6 CHF | +0.25% | -4.00% | +12.18% |
09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
04/04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 49% by 2026.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.18% | 516M | C+ | ||
+26.28% | 42.68B | B- | ||
-3.99% | 42.4B | B | ||
+45.32% | 40.04B | A | ||
-6.20% | 28.31B | C | ||
+6.36% | 24.94B | B- | ||
-21.47% | 18.96B | B | ||
+27.58% | 12.3B | C+ | ||
-2.75% | 11.95B | C+ | ||
-2.02% | 11.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BSLN Stock
- Ratings Basilea Pharmaceutica AG